Common cold antibodies yield clues to COVID-19 behavior
Among people who were never infected with the new coronavirus, a few
adults - and many children - may have antibodies that can neutralize
the virus, researchers reported on Friday in Science. Among 302 such
adults, 16 (5.3%) had antibodies, likely generated during infections
with "common cold" coronaviruses, that reacted to a specific region
of the spike protein on the new virus called the S2 subunit. Among
48 children and adolescents, 21 (43.8%) had these antibodies. In
test tube experiments, blood serum from both older and younger
uninfected individuals with cross-reactive antibodies could
neutralize the new coronavirus. That was not the case with serum
from study participants who lacked these antibodies. "Together,
these findings may help explain higher COVID-19 susceptibility in
older people and provide insight into whether pre-established
immunity to seasonal coronaviruses offers protection against
SARS-CoV-2," the publishers of the journal said in a statement. The
findings also suggest that targeting the S2 subunit on the
coronavirus spike protein might be the basis for a drug or vaccine
that works on multiple types of coronavirus. (https://bit.ly/3evCSFB)
Lung CT speeds COVID-19 diagnosis in stroke patients
In emergency-room patients with stroke, lung imaging studies can
help detect COVID-19 before results of nasal and throat swab tests
come back, researchers say. Stroke can be a sign of COVID-19, but
swab results can take days to become available. At three New York
City hospitals in March and April, doctors ordered computed
tomography angiograms (CTA) on 57 stroke patients within 24 hours of
hospital admission, to look for COVID-19-related pneumonia. Thirty
patients turned out to have COVID-19, based on their nasal swab
results.
But the CTA scans, in combination with patients' symptoms like cough
and shortness of breath, allowed for the diagnosis of COVID-19 with
83% accuracy before the swab test results were received. Screening
stroke patients for possible COVID-19 based only on symptoms is
unreliable, because they may not have symptoms or they might not be
able to speak, the researchers point out in their report in the
American Heart Association journal Stroke.
[to top of second column] |
"Early diagnosis via CT scans has helped our center protect other patients and
staff through early isolation, and it has also allowed us to start early
supportive care for those suspected of having stroke who are COVID-19 positive,"
coauthor Dr. Charles Esenwa of the Montefiore Medical Center said in a news
release. (https://bit.ly/3pbSCCH)
New coronavirus sneaks out of cells "with the trash"
The new coronavirus uses a surprising pathway to exit infected cells and go on
to infect others, researchers have discovered. It hijacks a cell structure
called the lysosome, which is normally where cellular trash goes to be
destroyed. But the virus uses lysosomes as escape hatches, the researchers
report in Cell. "To my knowledge coronavirus is one of 2 or 3 viruses to do
this, and certainly the only enveloped virus," said coauthor Nihal Altan-Bonnet
of the National Heart Lung and Blood Institute, referring to viruses that have a
membrane surrounding their genetic material. "All other enveloped viruses ...
use other pathways for cell-to-cell spread," Altan-Bonnet added. These include
influenza, hepatitis C, Dengue, Zika, West Nile and Ebola. When lysosomes
degrade bacteria and viruses into little pieces, she explained, "these little
pieces get presented on the surface of the cell to alert the immune system" to
the invaders' presence. By using the trash disposal system of the cell to get
out, the new coronavirus disables the lysosome and disrupts alerting the immune
system, she said. "We believe our discovery of the pathway used by coronaviruses
to get out of cells will be fundamental to our understanding of how these
viruses wreak havoc on our body, in particular our immune system." (https://bit.ly/36aBSmr)
Open https://tmsnrt.rs/3a5EyDh in an external browser for a Reuters graphic on
vaccines and treatments in development.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |